{"filing":{"accession_number":"0001570562-26-000083","cik":"0001570562","ticker":"EOLS","company_name":"Evolus, Inc.","form":"8-K","filing_date":"2026-08-04","report_date":"2026-08-03","primary_document":"eols-20260803.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1570562/000157056226000083/eols-20260803.htm"},"events":[{"id":23999,"run_id":21708,"accession_number":"0001570562-26-000083","anchor_item_number":"1.01","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"summary":"Evolus entered into a material amendment to its License, Supply and Distribution Agreement with Symatese on August 3, 2026, expanding exclusive commercialization rights for Estyme® to Canada, Australia, and New Zealand. The amendment includes €920,000 in upfront payments plus up to €1.38 million in regulatory milestone payments over a 15-year initial term per territory, representing a strategic expansion into markets with approximately $500 million in total addressable market.","company_name":"Evolus, Inc.","ticker":"EOLS","filing_date":"2026-08-04","form":"8-K","submitted_at":null,"items":[{"id":24373,"accession_number":"0001570562-26-000083","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Evolus entered into a material amendment to its existing License, Supply and Distribution Agreement with Symatese on August 3, 2026, expanding exclusive commercialization rights to Canada, Australia, and New Zealand for the Estyme® injectable hyaluronic acid gel portfolio. The amendment involves €920,000 in upfront payments plus up to €1.38 million in regulatory milestone payments, a 15-year initial term per territory, and represents a strategic expansion of the company's international commercial footprint into markets representing approximately $500 million in total addressable market. This constitutes a material definitive agreement under Item 1.01 that expands the company's product distribution rights and revenue opportunities across significant geographic markets.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:37:03.526414+00:00","company_name":"","ticker":null,"filing_date":""},{"id":24374,"accession_number":"0001570562-26-000083","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evolus announced an expansion of its strategic partnership with Symatese through an amendment to their licensing and distribution agreement, granting exclusive rights to commercialize Estyme® in Canada, Australia, and New Zealand with expected commercialization in 2028. This is a material operational and commercial event involving a significant product expansion into new geographic markets that leverages the company's existing infrastructure and strengthens its international portfolio, but it does not constitute a traditional M\u0026A transaction, debt issuance, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:37:03.526414+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":24373,"accession_number":"0001570562-26-000083","item_number":"1.01","item_title":"Entry into a Material Definitive Agreement.","event_type":"ma_activity","event_domain":"operational","is_material":true,"confidence":0.85,"reasoning":"Evolus entered into a material amendment to its existing License, Supply and Distribution Agreement with Symatese on August 3, 2026, expanding exclusive commercialization rights to Canada, Australia, and New Zealand for the Estyme® injectable hyaluronic acid gel portfolio. The amendment involves €920,000 in upfront payments plus up to €1.38 million in regulatory milestone payments, a 15-year initial term per territory, and represents a strategic expansion of the company's international commercial footprint into markets representing approximately $500 million in total addressable market. This constitutes a material definitive agreement under Item 1.01 that expands the company's product distribution rights and revenue opportunities across significant geographic markets.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:37:03.526414+00:00","company_name":"Evolus, Inc.","ticker":"EOLS","filing_date":"2026-08-04"},{"id":24374,"accession_number":"0001570562-26-000083","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"operational_other","event_domain":"operational","is_material":true,"confidence":0.75,"reasoning":"Evolus announced an expansion of its strategic partnership with Symatese through an amendment to their licensing and distribution agreement, granting exclusive rights to commercialize Estyme® in Canada, Australia, and New Zealand with expected commercialization in 2028. This is a material operational and commercial event involving a significant product expansion into new geographic markets that leverages the company's existing infrastructure and strengthens its international portfolio, but it does not constitute a traditional M\u0026A transaction, debt issuance, or other specifically-named event type.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-08-05T02:37:03.526414+00:00","company_name":"Evolus, Inc.","ticker":"EOLS","filing_date":"2026-08-04"}]}